ANGIODYNAMICS INC - 10-Q Summary (Q1 FY2026)
Business Context and Reporting Period
This report covers the quarterly period ended August 31, 2025 (First Quarter of Fiscal Year 2026). AngioDynamics, Inc. is a medical technology company focused on cardiovascular disease and cancer treatment, operating through two segments: Med Tech (Auryon, thrombus management, NanoKnife) and Med Device (Core, Venous, Ports, Oncology). The company is an accelerated filer with approximately 41.2 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 (Aug 31, 2025) | Q1 2025 (Aug 31, 2024) |
|---|---|---|
| Net Sales | $75.7 million | $67.5 million |
| Gross Margin | $41.9 million (55.3%) | $36.7 million (54.4%) |
| Operating Loss | $(10.7) million | $(13.1) million |
| Net Loss | $(10.9) million | $(12.8) million |
| Diluted Loss Per Share | $(0.26) | $(0.31) |
| Cash and Equivalents | $38.8 million | $55.0 million (end of period) |
| Operating Cash Flow | $(15.9) million | $(18.3) million |
| Long-Term Debt | $0 (No outstanding borrowings) | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12.2% year-over-year. The Med Tech segment drove this growth with a 26.1% increase, while Med Device grew 2.3%.
- Profitability Improvement: Net loss narrowed by $1.9 million. Gross margin expanded 90 basis points to 55.3%, aided by sales volume and mix, though partially offset by tariffs ($1.7 million negative impact).
- Expense Trends: Operating expenses increased by $2.7 million, primarily due to higher Sales and Marketing ($2.5M increase) and General and Administrative ($1.6M increase) costs. However, "Acquisition, restructuring and other items" decreased by $1.6 million due to lower plant closure expenses.
- Liquidity: Cash and cash equivalents decreased by $17.1 million during the quarter, driven by operating cash outflows and investing activities, though the company maintains a $25.0 million revolving credit facility with no current borrowings.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash and the revolving credit facility provide sufficient liquidity for at least the next 12 months. No specific forward-looking financial guidance was provided in this text.
- Restructuring: The company continues a restructuring plan announced in January 2024 to optimize its manufacturing footprint. Total estimated costs for the modified plan range from $33.4 million to $38.4 million. $2.3 million in charges were recorded in Q1 2026.
- Legal Contingencies:
- BD Settlement: A settlement with Becton, Dickinson and Company (BD) requires minimum annual payments of $2.5 million starting in FY2025, plus potential royalties. A contingent payment of $3.0 million is due if a pending Federal Circuit appeal is reversed. $2.5 million was paid in Q1 2026.
- Product Liability: The company is defending approximately 219 product liability claims related to port products.
- Risks: Key risks include macroeconomic factors (inflation, tariffs), supply chain challenges, regulatory actions, and the outcome of ongoing litigation.
Investor Verification Checklist
- Restructuring Progress: Verify the timeline and cash impact of the manufacturing footprint restructuring, specifically the modified plan to maintain a presence in Queensbury, NY.
- BD Settlement Obligations: Monitor the status of the Federal Circuit appeal regarding the BD patent litigation, as a $3.0 million contingent payment is at risk.
- Med Tech Growth Sustainability: Assess whether the 26.1% growth in the Med Tech segment (driven by Auryon and thrombus management) is sustainable given competitive pressures.
- Cash Burn Rate: Review the trend in operating cash flow usage ($15.9M in Q1) against the $38.8M cash balance to evaluate runway without additional financing.
- Tariff Impact: Evaluate the long-term impact of tariffs, which negatively affected gross margin by $1.7 million in this quarter.